Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of adjunctive XEN1101 for focal seizures
MOH_2023-09-11_012931Phase 3Not yet recruiting
- Sponsor
- .Xenon Pharmaceuticals Inc
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azetukalner in Focal Onset Epilepsy (3 arms), sponsored by .Xenon Pharmaceuticals Inc. Primary endpoint: Reduction in focal seizure frequency. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
azetukalner
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on MOH_2023-09-11_012931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-11_012931.